Navigation Links
HRID Announces Growth and Expansion
Date:3/1/2012

FORT LAUDERDALE, Fla., March 1, 2012 /PRNewswire/ -- Nouveau Life Pharmaceuticals, soon to be changed from Hybrid Fuels, Inc., (Pink Sheets: HRID) announced today that it is hiring a team of consumer marketing experts to position the Company as well as its current and pending portfolio of products to the market place.

The marketing team will focus initially on further developing the brand and consumer education strategy for the Azul Instant™ product.  Consumer response rates to the all-natural product offering have exceeded the Company's expectations to date and with the right marketing approach, the Company believes the product will quickly surpass competitive products globally. 

Nouveau Life's mission is to be the leading provider of safe and healthy remedies for those suffering with common medical conditions.  The Company's initial products have been developed to provide the millions of people suffering with sexual dysfunction with a solution comprised of all-natural ingredients.  Plans are now underway to expand the portfolio to launch all-natural supplements for weight loss, acne and high cholesterol.  The team of consumer marketing experts will be charged with building global brand strategies and consumer awareness campaigns across the Company's entire portfolio of product offerings.       

"Those of us that have been in the business for a long time can attest to the fact that marketing rules have changed.  Marketing strategies that worked just a few years ago are no longer producing the same results.  Consumers have more options today than any point in history.  We believe the key to our success is employing innovative marketing techniques to educate the consumer on our brands, reduce consumer risk, and utilize feedback to drive loyalty and satisfaction.  The selection of our marketing team was centered on these core principles," stated Ramiro Cadena, CEO of Nouveau Life Pharmaceuticals.  

The Company recently announced the introduction of Azul Instant™, an all-natural supplement for erectile dysfunction (ED) that provides the millions of men suffering from the condition with a safe alternative to prescription drugs.  Developed by a team of experts, the Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated. Unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects. 

About Azul Instant™

Azul Instant™ was developed by the scientific research and development team of Nouveau Life Pharmaceuticals to provide a safe and natural alternative for the millions of men suffering from erectile dysfunction.  The Company's goal is to create the healthiest and most effective all-natural male enhancer ever formulated.  Patients will now receive the NATURAL benefits of Azul Instant™ and unlike pharmaceutical drugs such as Cialis, Viagra and Levitra, Azul Instant™, carries no dangerous side effects.  While there are other natural alternative supplements on the market today, Azul Instant™ is the only male enhancement product that works as fast as 5 minutes.  Azul Instant™ can last for up to 48 hours and has proven to help enhance sexual stamina, endurance, strength and energy with no side effects. 

Azul Instant™ is marketed under Nouveau Life Pharmaceuticals, Inc.  For more information, go to www.azulnow.com

About Hybrid Fuels, Inc.

The company was incorporated in the state of Nevada in 1998 as Polo Equities.  It has primarily been a development stage company with management focused on developing innovative business opportunities and further advancing technologies. 

Forward-Looking Statements - This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties that could cause future results to differ materially from the forward-looking statements. You should consider these factors in evaluating the statements herein, and not rely on such statements. The forward-looking statements in this release are made as of the date hereof and Hybrid Fuels, Inc. undertakes no obligation to update such statements.

CONTACT:

Nouveau Life Pharmaceuticals, Inc. - 954-903-2993


'/>"/>
SOURCE Nouveau Life Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... -- Eli Lilly and Company (NYSE: LLY ... galcanezumab and lasmiditan, two investigational treatments for migraine, at ... taking place Sept. 7-10 in Vancouver ... data from an open-label study evaluating the safety and ... 240 mg) for the prevention of migraine. Galcanezumab is ...
(Date:9/5/2017)... -- Oramed Pharmaceuticals Inc. (NASDAQ: ORMP ) ... focused on the development of oral drug delivery systems, ... with the U.S. Food and Drug Administration (FDA) regarding ... At the meeting, the FDA ... of ORMD-0801, would be a Biologics License Application (BLA).  ...
(Date:8/29/2017)... 29, 2017 ivWatch, LLC, the leading provider of continuous ... it has been awarded an Innovative Technology contract from Vizient, Inc., ... ... aid in the early detection of peripheral IV infiltration and extravasation ... The Innovative Technology contract was awarded ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... ... methodology and industry-leading compliance software, The Guard®, has helped another long-time client pass ... HIPAA audit and properly satisfy the law. , Thanks to the help of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Five consumer packaged goods (CPG) ... impact in 27 different categories. Nopavera Plus was named to the short ... announced at SupplySide West 2017 during presentations at SupplySide Central on Sept. 27 and ...
(Date:9/20/2017)... ... September 20, 2017 , ... Recognising that in today’s busy ... Greeny delivers positive results in just three weeks. Setting the groundwork for a ... Fitting seamlessly into hectic work and family schedules, participants can lose up to ...
(Date:9/20/2017)... Texas (PRWEB) , ... September 20, 2017 , ... Houston, ... entire team took Friday, September 8, and Monday, September 11, off work and rolled ... Second Baptist Church before heading to local homes to start the process of rebuilding. ...
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: ... God; Second Edition” is the creation of published author, Brooks Rathell. , “We typically ... talk to you about the financial favor of God. Not only does it exist, ...
Breaking Medicine News(10 mins):